nach oben

rheuma plus

Erschienen in:

21.01.2020 | Kollagenosen

Systemische Sklerose

Teil 2: Therapie

verfasst von: Dr. H. Findeisen, H. Grasshoff, Prof. Dr. G. Riemekasten

Erschienen in: rheuma plus | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die systemische Sklerose ist eine seltene Autoimmunerkrankung – den Kollagenosen zugehörig. Vaskulopathie, Fibrose der Haut und Beteiligung der inneren Organe sind ausgesprochen heterogen und die Genese jener Krankheitsbilder bisher unverstanden. In den letzten Jahrzehnten sind einige Fortschritte im Management und in der Therapie erzielt worden, wobei weiterhin eher die Stabilisierung und Vermeidung von Krankheitssymptomen als die Verbesserung und Remissionserzielung erzielt werden können. In dieser Übersichtsarbeit möchten wir einen aktuellen Blick auf die wichtigen klinischen und therapeutischen Optionen werfen.

Vorheriger Artikel Bei Glukokortikoid-Langzeiteinnahme engmaschig Blutdruck kontrollieren

Nächster Artikel Hohes Fieber – wie geht es weiter?

Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 7. Mai 2009;360(19):1989–2003.

Wigley FM, Flavahan NA. Raynaud’s Phenomenon. Campion EW, Herausgeber. N Engl J Med. 11. August 2016;375(6):556–65.

Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73(7):1340–1349CrossRef

Jaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, Hachulla E et al (2016) Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE 11(10):e163894CrossRef

Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation. 8. November 2005;112(19):2980–5.

Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R et al (2010) Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatol Oxf Engl 49(12):2420–2428CrossRef

Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD953

Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, u. a. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1. Februar 1994;120(3):199–206.

Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19(5):503–508PubMed

10.

Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS‑2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70(1):32–38CrossRef

11.

Kuhn A, Haust M, Ruland V, Weber R, Verde P, Felder G, u. a. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology. 1. Juli 2010;49(7):1336–45.

12.

Del Papa N, Di Luca G, Andracco R, Zaccara E, Maglione W, Pignataro F, u. a. Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study. Arthritis Res Ther [Internet]. Dezember 2019 [zitiert 12. Oktober 2019];21(1). Verfügbar unter: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-018-1792-8

13.

Jaafar S, Visovatti S, Young A, Huang S, Cronin P, Vummidi D et al (2019) Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. Eur Respir J 2019 Aug 22;54(2). https://doi.org/10.1183/13993003.00586-2019 CrossRefPubMed

14.

Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327–1339CrossRef

15.

Kuzuya K, Tsuji S, Matsushita M, Ohshima S, Saeki Y. Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat. Cureus. 26. März 2019;11(3):e4327.

16.

Humbert M, Coghlan JG, Ghofrani H‑A, Grimminger F, He J‑G, Riemekasten G et al (2017) Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT‑1 and PATENT‑2. Ann Rheum Dis 76(2):422–426CrossRef

17.

Ngian G‑S, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, u. a. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther. 5. Oktober 2012;14(5):R213.

18.

Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian G‑S et al (2017) Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Res Ther 19(1:122CrossRef

19.

Galiè N, Barberà JA, Frost AE, Ghofrani H‑A, Hoeper MM, McLaughlin VV, u. a. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 27. August 2015;373(9):834–44.

20.

Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, u. a. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 1. November 2015;192(9):1102–10.

21.

Willems LM, Vriezekolk JE, Schouffoer AA, Poole JL, Stamm TA, Boström C et al (2015) Effectiveness of Nonpharmacologic Interventions in Systemic Sclerosis: A Systematic Review. Arthritis Care Res 67(10):1426–1439CrossRef

22.

Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44(6):1351–1358CrossRef

23.

Distler O, Volkmann ER, Hoffmann-Vold AM, Maher TM. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol. 2019 Oct;15(10):1009–1017. https://doi.org/10.1080/1744666X.2020.1668269

24.

Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719CrossRef

25.

Moazedi-Fuerst F, Kielhauser S, Brickmann K, Hermann J, Lutfi A, Meilinger M et al (2014) Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen. Scand J Rheumatol 43(3):257–258CrossRef

26.

van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, u. a. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 25. Juni 2014;311(24):2490–8.

27.

Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 15. März 2018;378(11):1066–7.

28.

Poormoghim H, Rezaei N, Sheidaie Z, Almasi AR, Moradi-Lakeh M, Almasi S et al (2014) Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement‑a retrospective study. Rheumatol Int 34(12):1691–1699CrossRef

29.

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, u. a. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. N Engl J Med. 27. Juni 2019;380(26):2518–28.

30.

Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, u. a. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 1. Juli 2015;125(7):2795–807.

31.

Lee ATY, Burnet S. Corticosteroid-induced scleroderma renal crisis. Med J Aust. 21. Oktober 2002;177(8):459.

32.

Vignaux O, Allanore Y, Meune C, Pascal O, Duboc D, Weber S et al (2005) Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis 64(9):1268–1273CrossRef

33.

Allanore Y, Meune C, Vignaux O, Weber S, Legmann P, Kahan A (2006) Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J Rheumatol 33(12):2464–2469PubMed

34.

Valentini G, Huscher D, Riccardi A, Fasano S, Irace R, Messiniti V, u. a. Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Ann Rheum Dis.2019 Nov;78(11):1576–1582. https://doi.org/10.1136/annrheumdis-2019-215486

35.

De Luca G, Bosello SL, Gabrielli FA, Berardi G, Parisi F, Rucco M et al (2016) Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome. PLoS ONE 11(4):e153012CrossRef

36.

Pieroni M, De Santis M, Zizzo G, Bosello S, Smaldone C, Campioni M et al (2014) Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum 43(4):526–535CrossRef

37.

Fernández-Codina A, Simeón-Aznar CP, Pinal-Fernandez I, Rodríguez-Palomares J, Pizzi MN, Hidalgo CE et al (2017) Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival. Rheumatol Int 37(1):75–84CrossRef

38.

Fernández-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol Hoboken NJ. (2018) 70(11), S 1820–1828

39.

Furnari M, Savarino V, de Bortoli N, Savarino E (2016) Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. Autoimmun Rev 15(12):1208–1209CrossRef

40.

Vigone B, Caronni M, Severino A, Bellocchi C, Baldassarri AR, Fraquelli M et al (2017) Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther 19(1:145CrossRef

41.

Pittman N, Rawn SM, Wang M, Masetto A, Beattie KA, Larché M. Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. Rheumatology. 1. Oktober 2018;57(10):1802–11.

42.

Traineau H, Aggarwal R, Monfort J‑B, Senet P, Oddis CV, Chizzolini C, u. a. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: a review of the literature. J Am Acad Dermatol [Internet]. Juli 2019 [zitiert 12. Oktober 2019]; Verfügbar unter: https://linkinghub.elsevier.com/retrieve/pii/S0190962219323187

43.

Allanore Y, Devos-François G, Caramella C, Boumier P, Jounieaux V, Kahan A (2006) Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 65(6):834–835CrossRef

44.

Valenzuela A, Calcinosis CL (2015) pathophysiology and management. Curr Opin Rheumatol 27(6):542–548CrossRef

45.

Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI et al (2001) Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatol Oxf Engl 40(9):1038–1043CrossRef

Titel: Systemische Sklerose
Teil 2: Therapie
verfasst von: Dr. H. Findeisen
H. Grasshoff
Prof. Dr. G. Riemekasten
Publikationsdatum: 21.01.2020
Verlag: Springer Vienna
Erschienen in: rheuma plus / Ausgabe 3/2020
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI: https://doi.org/10.1007/s12688-019-00315-4

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Stellenwert der Januskinasen

Bei Glukokortikoid-Langzeiteinnahme engmaschig Blutdruck kontrollieren

Hohes Fieber – wie geht es weiter?

Rheuma-Patienten reagieren sensibler auf Salz

Schwere Infekte nach psychischer Belastung

Übergewicht hemmt die Wirkung von Medikamenten